Targeting PDE4 drives anti-inflammatory and antifibrotic effects, and Boehringer has been working on its own PDE4 inhibitor ...

The increased investment in China by Boehringer Ingelheim is part of a larger trend of German businesses expanding operations in the Chinese market, even as some European politicians have been ...

Boehringer Ingelheim’s biopharmaceutical facility in Shanghai, China, meets the conditions to participate in a regulatory reform promoting segmented manufacturing of biological products by the local ...

Boehringer Ingelheim is on track in its target to become ... including Japan and China. A new biomass power plant was also commissioned at its Ingelheim site in Germany to boost on-site renewable ...

Results presented at this year’s American Thoracic Society International Conference showed that the trials met their primary ...